Sellas Life Sciences Group Inc (SLS) - Total Liabilities
Based on the latest financial reports, Sellas Life Sciences Group Inc (SLS) has total liabilities worth $7.73 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check SLS asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Sellas Life Sciences Group Inc - Total Liabilities Trend (2007–2025)
This chart illustrates how Sellas Life Sciences Group Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see SLS total asset value.
Sellas Life Sciences Group Inc Competitors by Total Liabilities
The table below lists competitors of Sellas Life Sciences Group Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
China Science Publishing & Media Ltd
SHG:601858
|
China | CN¥1.68 Billion |
|
Oyak Cimento Fabrikalari AS
IS:OYAKC
|
Turkey | TL17.35 Billion |
|
Cadeler A/S
NYSE:CDLR
|
USA | $1.85 Billion |
|
Douzone Bizon Co Ltd
KO:012510
|
Korea | ₩517.29 Billion |
|
ShenZhen QiangRui Precision Technology Co. Ltd.
SHE:301128
|
China | CN¥1.49 Billion |
|
Wisdom Marine Lines Co Ltd
TW:2637
|
Taiwan | NT$1.05 Billion |
|
Zhejiang Changsheng Sliding Bearings Co Ltd Class A
SHE:300718
|
China | CN¥275.46 Million |
|
Hangzhou Robam Appliances Co Ltd
SHE:002508
|
China | CN¥4.78 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down Sellas Life Sciences Group Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Sellas Life Sciences Group Inc to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 18.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sellas Life Sciences Group Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sellas Life Sciences Group Inc (2007–2025)
The table below shows the annual total liabilities of Sellas Life Sciences Group Inc from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.47 Million | -25.01% |
| 2024-12-31 | $9.97 Million | -29.79% |
| 2023-12-31 | $14.20 Million | -11.79% |
| 2022-12-31 | $16.09 Million | +164.67% |
| 2021-12-31 | $6.08 Million | -66.39% |
| 2020-12-31 | $18.09 Million | +72.00% |
| 2019-12-31 | $10.52 Million | -9.89% |
| 2018-12-31 | $11.67 Million | -62.90% |
| 2017-12-31 | $31.46 Million | -15.34% |
| 2016-12-31 | $37.15 Million | -45.86% |
| 2015-12-31 | $68.63 Million | +58.03% |
| 2014-12-31 | $43.43 Million | -47.10% |
| 2013-12-31 | $82.09 Million | +201.47% |
| 2012-12-31 | $27.23 Million | +30.56% |
| 2011-12-31 | $20.86 Million | +313.32% |
| 2010-12-31 | $5.05 Million | -8.44% |
| 2009-12-31 | $5.51 Million | +296.19% |
| 2008-12-31 | $1.39 Million | +5.06% |
| 2007-12-31 | $1.32 Million | -- |
About Sellas Life Sciences Group Inc
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or … Read more